Monday, March 17, 2014
Ltd.'s phenotypic screening platform will provide Roche
with a tool to probe narrow-spectrum antibacterials as the pharma makes its
return to antibiotics development. The companies partnered late last month to
use Discuva's bacterial transposon libraries, next-generation sequencing and
bioinformatics, which can identify the targets and resistance mechanisms for
new pathogen-specific antibiotics in a matter of days.
The companies will discover and
develop antibacterials for multidrug-resistant (MDR) Gram-negative bacteria
using Discuva's selective antibiotic target identification (SATIN) technology.
Discuva will receive $16 million up front and is eligible for up to $175
million in development, commercialization and sales milestones per product,
plus up to double-digit royalties.